Randall Parker writes about the biggest barrier to medical advances:

If you read the full article above you’ll learn that the first experimental subjects for a Novato California company were in Argentina – not exactly close by. I suspect this says something about medical regulation in America today. The Argentines were on hemodialysis for kidney failure and had what the report below characterized as “typical risk factors for end-stage renal disease”. You might expect regulatory agencies to grant greater freedom of action to try out new treatments on people who are looking death in face. But this company used subjects from another country. I fear excessive regulatory obstacles in the way of new treatment development are costing lots of lives.

I suspect that the FDA probably kills more people by delaying the introduction of new drugs and procedures than it saves. But it’s like protectionist policies and other interferences with the market–the jobs and businesses that aren’t created are an invisible consequence compared to existing jobs that are lost, and a bureaucrat is much more concerned about being blamed for a death that results from a new drug than one that results from its delay, because the latter is just a maintenance of the status quo.

Randall also has bad news about avian flu. It may be easier for it to mutate to affect humans than we thought.